Agile Therapeutics Inc. (AGRX) Given Average Recommendation of “Buy” by Analysts
Agile Therapeutics Inc. (NASDAQ:AGRX) has earned an average rating of “Buy” from the six analysts that are presently covering the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $16.00.
AGRX has been the topic of a number of recent analyst reports. FBR & Co reaffirmed a “buy” rating on shares of Agile Therapeutics in a research note on Friday, June 17th. Noble Financial reaffirmed a “buy” rating and issued a $15.00 target price on shares of Agile Therapeutics in a research note on Friday, July 8th.
Agile Therapeutics (NASDAQ:AGRX) traded down 2.03% during midday trading on Thursday, hitting $7.25. 5,177 shares of the stock were exchanged. The company’s 50 day moving average is $7.27 and its 200-day moving average is $6.99. Agile Therapeutics has a 1-year low of $5.32 and a 1-year high of $10.41. The stock’s market cap is $208.45 million.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, meeting analysts’ consensus estimates of ($0.29). On average, analysts expect that Agile Therapeutics will post ($1.26) earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of AGRX. Teachers Advisors Inc. increased its position in Agile Therapeutics by 30.2% in the second quarter. Teachers Advisors Inc. now owns 19,401 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 4,497 shares during the period. TFS Capital LLC acquired a new position in Agile Therapeutics during the second quarter valued at approximately $164,000. AlpInvest Partners B.V. acquired a new position in Agile Therapeutics during the second quarter valued at approximately $211,000. BlackRock Investment Management LLC increased its position in Agile Therapeutics by 9.3% in the second quarter. BlackRock Investment Management LLC now owns 45,455 shares of the specialty pharmaceutical company’s stock valued at $346,000 after buying an additional 3,855 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Agile Therapeutics by 11.1% in the second quarter. Bank of New York Mellon Corp now owns 63,612 shares of the specialty pharmaceutical company’s stock valued at $484,000 after buying an additional 6,355 shares during the period. 84.13% of the stock is currently owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.